Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is a healthcare company, listed on the NASDAQ. Alpha Stocks Insight has published 2 articles on VRTX since Thursday, July 2, 2026, most recently "Vertex Pharmaceuticals (NASDAQ:VRTX) Raises 2026 Revenue Guidance to $13.1B-$13.2B After Q2 Beat" on Monday, August 3, 2026. Coverage to date spans Earnings Report and Health Care, tracking VRTX's earnings, analyst activity, and material corporate events. New coverage is added each trading day.
Vertex posted $3.33B in Q2 revenue, up 12% YoY, but flat non-GAAP net income indicates rising costs from JOURNAVX launch and renal expansion.
The FDA expanded CASGEVY's label to patients ages 2 and older with sickle cell disease or beta thalassemia, marking the first gene therapy cleared for young children with SCD.
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.
Important Legal Disclaimer: This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.